

Table 1. Detection of antiviral drug-resistant viruses in Japan during the 2022/2023 influenza season

as of May 9, 2025

	A(H1N1)pdm09						A(H3N2)						B				
	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir	Amantadine	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir	Amantadine	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir
Resistant (%)	0	0	0	0	0	36 (100%)	8 (1.7%)	0	0	0	0	275 (100%)	0	0	0	0	0
Number of viruses tested	38	53	53	35	35	36	477	274	274	274	274	275	41	39	39	39	39
Number of viruses reported	111						3,181						84				

Baloxavir was examined by focus reduction assay, rhPCR allelic discrimination and/or PA sequencing.
NA inhibitors were examined by fluorescence-based NA-Fluor assay, chemiluminescence-based NA-XTD assay, real time RT-PCR allelic discrimination and/or NA sequencing.
Amantadine was examined by M2 sequencing.